NIH Study Sections 2026: ART and Assignment Requests
Updated 10 official sources
Quick Answer: For NIH researchers and grant writers, study sections perform first-level peer review; use ART to find candidates, verify live scopes, then put preferences in the PHS Assignment Request Form.
Full answer and how we checked it
NIH makes the final assignment. Don't trust ART alone because CSR says many panels introduced in summer 2026 won't appear there until fall 2026.
This guide is for investigators, research administrators, and grant writers choosing an NIH study section or interpreting a 2026 peer-review result. Based on our review of 10 current NIH and CSR source surfaces, the strongest assignment evidence comes from the exact opportunity, live panel scope, roster coverage, RePORTER analogs, and clearly described expertise needs. ART supplies candidates, not the final answer.
Data note: Grantsights checked NIH and CSR assignment, submission, panel, roster, first-level review, simplified-review, and 2026 discussion-status guidance on September 10, 2026. Panel scopes, rosters, meetings, and temporary review policies can change. Use the exact funding opportunity and current NIH record for the application being prepared.
In this guide
- The 2026 Study Section Answer in One Table
- What CSR Doesn't Tell You in One Place
- What an NIH Study Section Does
- Which Panel Type Owns the Application?
- How to Choose an NIH Study Section
- How to Complete the PHS Assignment Request Form
- What the SRO Does
- NIH Scoring Under the Simplified Review Framework
- Competitive but Not Discussed in 2026
- What Happens After the Meeting
- When a Review Appeal Is Appropriate
- Study Section Checklist
- Sources
- Maintenance Rule
An NIH study section answers one question: does the proposed project have scientific and technical merit? It does not make the final funding decision. The assigned NIH institute or center performs the second level of review, considers program priorities and available funds, and its director makes the award decision.
The applicant's useful job is not to predict friendly reviewers. It is to give NIH a source-backed assignment request that matches the application's central aims, methods, population, and required expertise. This guide provides that workflow and explains the 2026 peer-review rules that affect what applicants see after the meeting.
The 2026 Study Section Answer in One Table
| Decision | Current answer | Source to check |
|---|---|---|
| Who assigns the application? | CSR's Division of Receipt and Referral assigns a study section and one or more institutes or centers. NIH staff make the final assignment. | CSR assignment process |
| Can the applicant suggest a panel? | Yes. The optional PHS Assignment Request Form can name preferred or nonpreferred study sections. | CSR submission process and NIH's August 2026 reminder |
| Should the request go in a cover letter? | No. CSR says assignment requests belong in the PHS form. | CSR submission process |
| Is ART the final answer? | No. ART recommends candidates, and CSR warns that new summer 2026 panels will not appear until fall 2026. | CSR ART page and live panel directory |
| Who appears on a roster? | The meeting list can include standing and temporary reviewers and is tentative. A membership panel shows chartered members only. | Current panel page and roster |
| Who makes the award decision? | The study section assesses merit. The institute or center completes later review and the director makes the funding decision. | NIH review overview |
The fastest safe route is: identify two or three plausible panels, compare their actual scopes and current rosters, test similar funded work in RePORTER, and submit a concise assignment request. Do not choose a panel from its acronym alone.
Source review by Grantsights
We compared the 2026 ART update note, current panel directory, submission and assignment instructions, NIH's August PHS-form reminder, current peer-review framework, and temporary discussion rules. Based on our analysis, the gap is practical: the tools are spread across separate NIH surfaces, while the applicant must reconcile them into one panel request and one post-review interpretation. Our comparison found two current stop signals that an older study-section guide can miss: ART's summer 2026 panel lag and the temporary competitive-but-not-discussed category through the October 2026 Council round.
According to CSR's February 26, 2026 ART page, many new study sections began in summer 2026 and will not enter ART until fall 2026. According to NIH's April 27, 2026 applicant guidance, temporary backlog rules reduced discussion from approximately 50% to 33% for affected reviews through the October 2026 Council round. Those two dated facts change both the pre-submission panel check and the post-meeting result interpretation.
What CSR Doesn't Tell You in One Place
CSR publishes the authoritative panel scopes, rosters, contacts, and ART entry point. It does not put the exact opportunity, ART's current update lag, RePORTER analogs, PHS form fields, simplified scoring, and temporary 2026 discussion status into one applicant decision.
The common mistake is treating a tool output or a familiar reviewer as the answer. A defensible assignment request needs agreement across the central question, method, population, opportunity, and panel scope. If those units disagree, the honest next action is to narrow the request or ask the listed SRO about fit, not to force the most familiar acronym.
What an NIH Study Section Does
NIH calls a study section a Scientific Review Group, or SRG. It is composed primarily of nonfederal scientists with expertise in the disciplines and current research areas needed for review. The group assesses the likely overall impact of the proposed project, resource, training activity, or center.
NIH separates peer review from funding. This boundary matters when interpreting a result:
- The study section performs the first level of review and evaluates merit.
- A National Advisory Council or Board performs the second level of review.
- The institute or center director makes the funding decision.
A strong study-section result is not an award promise. It also does not prove which institute will pay, when an award will start, or whether a program priority will affect selection. Use the NIH grants guide for mechanism choice and the NIH R01 hub for current R01 route checks before treating panel fit as the only decision.
Which Panel Type Owns the Application?
CSR organizes study sections inside Review Branches. Applications generally move first to a branch and then to a specific review group. The live directory separates several panel types.
| Panel type | Typical job | Applicant check |
|---|---|---|
| Chartered study section | Many investigator-initiated R01, R03, R21, R15, and K applications | Compare the scientific scope, overlap notes, current meetings, and roster |
| SBIR/STTR recurring Special Emphasis Panel | Small-business research and technology-transfer applications | Use the SBIR/STTR mode in ART and confirm the exact opportunity's review location |
| Fellowship recurring Special Emphasis Panel | Individual F30, F31, F32, and F33 fellowship applications | Use the fellowship mode in ART and current fellowship review criteria |
| Other Special Emphasis Panel | Special initiatives, conflict applications, or a defined topic or mechanism | Follow the exact opportunity and the panel's live scope rather than a standing-panel assumption |
| Institute or center review group | Applications assigned outside a CSR standing panel | Use the opportunity and eRA Commons assignment as the controlling record |
Standing does not mean unchanging. CSR can update scopes and can recruit temporary reviewers for a meeting. Special Emphasis Panel does not mean lower quality or a less formal review. It identifies a different panel structure and staffing pattern.
How to Choose an NIH Study Section
Use a six-source assignment screen. No single source should control the answer.
1. Start with the exact funding opportunity
Read the opportunity's review criteria and review-location language. A notice can establish a specific panel, institute review group, or Special Emphasis Panel. Mechanism labels alone do not prove review location.
The NIH research project cluster helps separate R01, R03, R21, R15, R35, U01, and adjacent routes. The assignment exercise begins after the team has selected the correct opportunity and trial lane.
2. Use ART to create candidates
CSR's Assisted Referral Tool accepts scientific text and recommends potentially appropriate study sections. According to CSR, the submitted text is used for recommendations and is not stored or persisted. ART has three modes: general study sections, SBIR/STTR panels, and fellowship panels.
ART is a discovery tool, not assignment evidence by itself. CSR's February 2026 page says many new study sections began in summer 2026 and will not be reflected in ART until fall 2026. It also identifies the tool's data refresh as October 2025. A candidate from ART therefore needs a live-directory check before it goes on the PHS form.
3. Read the live scope and overlap notes
Open each candidate in CSR's current study-section directory. Compare the application's central hypothesis, aims, methods, population, intervention, disease area, and data type with the published topics. Read any shared-interest or overlap notes because many projects sit between panels.
Use this short comparison table for each candidate:
| Fit unit | Evidence to record | Stop signal |
|---|---|---|
| Central question | One sentence connecting the main aim to the panel scope | Only a disease keyword matches |
| Methods | The panel lists or routinely reviews the main method | The method is peripheral or absent |
| Population or system | The panel covers the studied population, model, or setting | A nearby panel owns the actual population |
| Cross-disciplinary component | The scope or overlap note supports the secondary field | The secondary field carries the central causal claim |
| Mechanism and notice | The opportunity can reach this panel | Review location is predetermined elsewhere |
4. Inspect current and recent rosters carefully
The meeting roster is evidence about available expertise, not a list of likely assigned reviewers. Current CSR panel pages explain that the list of reviewers includes those expected at that meeting, can include standing and temporary members, and remains tentative. Many panel pages post a roster at least 30 days before the meeting.
Use the roster to ask whether the panel has coverage for the application's core methods and subject area. Do not request a panel because one favorable person appears. Do not name desired reviewers. The PHS form can identify people who should not review because of a potential conflict and can describe expertise needed, but the applicant should not nominate reviewers.
5. Use RePORTER as an analogy check
NIH encourages applicants to search RePORTER for related funded work and see where it was reviewed. Treat those records as analogies, not precedent. A historic award does not prove current panel scope, current institute interest, or a future outcome.
Compare several projects and record why they are similar: scientific question, method, population, mechanism, and institute. One keyword match or one famous laboratory is weak evidence.
6. Resolve disagreement before submission
If ART, the live scope, rosters, and RePORTER point to different panels, narrow the request or ask the listed SRO or referral staff about fit. The final request should be explainable from the application itself. If two strong panels remain, the PHS form can rank preferences while NIH retains assignment authority.
How to Complete the PHS Assignment Request Form
According to NIH's August 12, 2026 reminder, the optional form is available in nearly all competing application packages. NIH says it is shared with appropriate review staff, not reviewers or others at NIH, and is not included in the assembled application.
The form can communicate four things:
- Suggested institute, center, or office assignments.
- Suggested study sections.
- People who may have a conflict with reviewing the application.
- Scientific expertise needed for the review.
Write the request around science and review needs. A useful study-section preference can connect the central aim and main method to a published panel scope. An expertise request should describe a field, method, or population, not a preferred person's name.
Assignment request example
In a hypothetical example, one university in California is preparing an R01 that tests a behavioral intervention using genomic biomarkers. ART returns both a behavioral panel and a genomics panel. The live scopes show that intervention implementation is the main scientific question and genomics is a measurement layer. Recent rosters show intervention and implementation expertise in the behavioral panel. RePORTER shows several methodologically similar projects there.
The evidence supports a behavioral-panel preference and a request for genomic-biomarker expertise. It does not support choosing the genomics panel solely because the application contains sequencing data.
What belongs in the cover letter instead?
Current CSR submission guidance says not to use the cover letter for assignment requests. A cover letter can address information outside the PHS form, such as continuous-submission eligibility or a late-submission explanation. Follow the current application guide and the exact opportunity for any required letter.
What the SRO Does
The Scientific Review Officer manages the review process but does not make the funding decision. CSR describes several core duties:
- Confirming whether assigned applications fit the review group and seeking reassignment when they do not.
- Recruiting reviewers with the expertise needed for the applications.
- Assigning applications to reviewers based on scientific fit.
- Managing conflicts and applying review policy.
- Running the meeting process and preparing the summary statement.
After assignment appears in eRA Commons, contact the listed SRO promptly if the panel seems unsuitable. State the scientific mismatch and the better scope. Do not argue that a panel is unfavorable or seek a particular reviewer. NIH staff decide whether reassignment is warranted.
NIH Scoring Under the Simplified Review Framework
For most affected research project grant applications with due dates on or after January 25, 2025, NIH reorganized five regulatory criteria into three factors.
| Factor | What it covers | Treatment |
|---|---|---|
| Factor 1: Importance of the Research | Significance and innovation | Scored from 1 to 9 |
| Factor 2: Rigor and Feasibility | Approach, plus applicable inclusion and clinical-trial timeline elements | Scored from 1 to 9 |
| Factor 3: Expertise and Resources | Investigators and environment | Evaluated for sufficiency; gaps require explanation |
All three factors inform overall impact. Factor 3 has no separate numerical criterion score under this framework. NIH says the same research strategy is reviewed in a new way, and applicants must verify whether their activity code and opportunity use the framework.
The affected list includes common research project codes such as R01, R03, R15, R16, R21, R33, R34, R36, R61, U01, U34, and several phased and cooperative-agreement codes. NIH states that small-business and complex multi-project grants are not included. Section V of the exact opportunity remains the correct review-criteria source.
Use the NIH grant score guide for score interpretation and the summary statement guide for post-review triage.
Competitive but Not Discussed in 2026
NIH introduced temporary review modifications after a lapse in appropriations created an application backlog. According to NIH's April 27, 2026 explanation, the changes remain through the October 2026 Advisory Council round.
Under the temporary approach, the approximate discussion rate moved from 50% to 33% for affected reviews. NIH identifies the middle third as competitive but not discussed. These applications:
- Are not discussed at the meeting.
- Do not receive a priority score.
- Do not receive a resume of discussion.
- Do receive written critiques from three assigned reviewers.
That status is not the same as a scored discussed application, and it is not the same as an application outside the competitive group. Read the written critiques, verify whether the temporary rule applied to the review, and speak with the program official before choosing a resubmission path. Use the NIH resubmission guide only after that diagnosis.
What Happens After the Meeting
According to NIH's current first-level review page, scores are typically released in eRA Commons within 3 business days and summary statements within about 30 days. A summary statement can contain the impact score, a percentile when applicable, criterion assessments, reviewer critiques, and a brief discussion summary for an application that was discussed.
A percentile compares the application's impact score with applications reviewed by the same committee in the current and preceding two review rounds. Not every application receives a percentile. A percentile does not replace institute-specific funding context, and it is not a universal payline.
The second-level Advisory Council or Board then provides recommendations. The institute or center director makes the final decision. Before reading a result as fundable or unfundable, separate four records:
| Record | What it answers |
|---|---|
| eRA Commons assignment | Which study section and institute or center own the application |
| Score and summary statement | How the scientific review was recorded |
| Institute guidance or program contact | How the institute is treating the application in context |
| Notice of Award | Whether NIH actually made an award |
From Manusights, our sister product
After the meeting, your summary statement decides what you fix for the next round.
Manusights offers an AI critique of NIH applications against NIH's review criteria. For a resubmission, you upload your summary statement and your application. Each critique is sorted into “the reviewers missed it”, “we were unclear” or “a real flaw”, and the fixes are ranked by the criterion each one moves. Writing a new F31, F32, R01 or R21? It critiques those before you submit, too.
It's critique only. It never writes any part of your application, gives no score, and doesn't predict whether you'll be funded. NIH has no part in it.
Order online: $49 for an F31 or F32, $149 for a new R01, R21 or K award application, $199 for a resubmission plan. Back within 3 business days of your upload.
Order a grant reviewWhen a Review Appeal Is Appropriate
NIH provides an appeal path when an applicant organization believes the initial review process was flawed because of reviewer bias, a conflict of interest, missing appropriate expertise, or factual errors that could have changed the outcome. Disagreement with scientific judgment by itself is not the appeal standard.
Start with the summary statement and institutional research office. Identify the claimed process flaw and the record that supports it. Keep ordinary scientific disagreement in the revise-and-resubmit decision rather than relabeling it as procedural error.
Study Section Checklist
Before submission:
- Confirm the exact opportunity, activity code, and review criteria.
- Run ART in the correct general, fellowship, or SBIR/STTR mode.
- Recheck every ART suggestion against the live CSR directory.
- Compare scope, overlap notes, current rosters, and several RePORTER analogs.
- Put assignment preferences, exclusions, and expertise needs in the PHS Assignment Request Form.
- Keep assignment requests out of the cover letter.
After submission:
- Check eRA Commons for the assigned study section and institute or center.
- Contact the listed SRO promptly if the scientific scope is a poor fit.
- Confirm the live meeting and roster rather than relying on an old calendar.
- Read the score, discussion status, and summary statement as separate fields.
- Ask the program official about institute context before choosing a resubmission.
The right outcome is not a guaranteed panel. It is an assignment record that matches the science, a review-status interpretation that matches current NIH policy, and a documented next action.
Sources
- CSR Study Sections (opens in a new tab), current branches, chartered panels, fellowship panels, SBIR/STTR panels, and other Special Emphasis Panels.
- CSR Assisted Referral Tool (opens in a new tab), current tool status and the summer-to-fall 2026 panel-update warning.
- CSR ART (opens in a new tab), candidate-panel recommendations and operating modes.
- CSR Submission Process (opens in a new tab), PHS form uses and cover-letter boundary.
- CSR Assignment Process (opens in a new tab), staff authority and assignment inputs.
- NIH PHS Assignment Request Form reminder (opens in a new tab), August 12, 2026 applicant guidance.
- NIH First Level: Peer Review (opens in a new tab), study-section role, results, percentiles, and appeal grounds.
- NIH Simplified Review Framework (opens in a new tab), affected applications and three-factor review.
- NIH competitive-but-not-discussed explanation (opens in a new tab), temporary 2026 review status.
- NIH RePORTER (opens in a new tab), funded-project and study-section analogy research.
Maintenance Rule
Recheck the CSR ART update note, live study-section directory, PHS form guidance, simplified-review scope, and temporary discussion-status notices at least every 30 days. Recheck the exact panel and opportunity before every submission.
Use this guide with the NIH grants hub, NIH R01 hub, NIH K awards hub, NIH grant score guide, summary statement guide, and NIH resubmission guide.
Get research funding calls by email
About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.
No spam. Unsubscribe anytime.
NIH study section route chooser
Decide whether the issue is review home, route choice, aims, or award evidence
Study-section searches usually mean the applicant is close to writing or resubmitting. Pick the path that answers whether reviewers, institute fit, mechanism, and funded examples support the next NIH cycle.
Open R01 route index
Compare parent notices, trial lanes, institute fit, and resubmission timing for R01 pages.
See NIH R01 grantsNext stepCheck R01 success rates
Use current R01-equivalent data before choosing a broad R01 cycle or a narrower route.
Read the guideNext stepPlan A1 or new A0
Use this after summary statement review to decide whether the same review home is worth another try.
Read the guideNext stepFix Specific Aims
Use this when the aims, hypothesis, and reviewer logic need work before program officer review.
Read the guideNext stepFind grants that fit you
Free eligibility check: answer 12 questions and see ranked matches with deadlines and fit reasons.
Check eligibilityNext stepCompare nearby mechanisms
Use this when study-section fit suggests R21, R03, K, or another NIH path may be cleaner than R01.
Read the guideStudy-section fit
Reviewers understand the model, method, field, and endpoint without a long translation burden.
Program fit
The institute, activity code, and funding posture make sense before the application reaches review.
Rewrite signal
If critiques show the wrong review home or mechanism, route choice should change before the next draft.
Frequently Asked Questions
What is an NIH study section?
An NIH study section, formally called a Scientific Review Group, performs the first level of peer review. It assesses scientific and technical merit. An NIH institute or center handles the second level of review and the institute or center director makes the funding decision.
Can I request a specific NIH study section?
Yes. NIH encourages applicants to use the optional PHS Assignment Request Form. You may suggest institute or center assignments and study sections, identify people with potential conflicts, and name expertise needed for review. NIH considers the request but makes the final assignment.
Should an NIH study section request go in the cover letter?
No. Current CSR submission guidance says assignment requests belong in the PHS Assignment Request Form. The cover letter is for information not covered there, such as continuous-submission eligibility or a late-submission explanation.
Is the NIH Assisted Referral Tool current in 2026?
Use ART as a candidate generator, not a final authority. CSR says many new study sections began in summer 2026 and would not appear in ART until fall 2026. Compare every ART result with the live study-section scope, current roster, and the exact funding opportunity.
How does NIH score applications under the simplified review framework?
For most affected research project grant applications with due dates on or after January 25, 2025, Factor 1, Importance of the Research, and Factor 2, Rigor and Feasibility, receive 1-to-9 scores. Factor 3, Expertise and Resources, is evaluated for sufficiency and still informs overall impact. The exact funding opportunity controls.
What does competitive but not discussed mean at NIH in 2026?
Under temporary NIH review modifications that remain through the October 2026 Advisory Council round, the middle third of some applications can be labeled competitive but not discussed. NIH says these applications receive written critiques from three assigned reviewers but no priority score or resume of discussion.
Last updated September 10, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
Complete Guide
NIH Grants 2026: R01, K Awards, R21, R35, SBIR
Compare NIH R01, K awards, R21, R03, R35, SBIR/STTR, success rates, deadlines, and program pages before choosing a route.
How to Read an NIH Summary Statement: Scores and Critiques
Your NIH summary statement has 3 reviewers' critiques and, if discussed, a 10-90 impact score. Decode the wording and decide: resubmit, revise or switch.
NIH Resubmission (A1): 1 Try, 37 Months, 1-Page Intro
NIH allows one A1 resubmission within 37 months of the A0, with a one-page Introduction. When to resubmit, when to go new, and how to answer reviewers.
NIH Specific Aims Page: 1-Page Structure and 2-3 Aims
Write the 1-page NIH Specific Aims: what is known, the gap, your objective and hypothesis, then 2-3 independent aims with expected outcomes and impact.
NIH Biosketch 2026: Format, Sections & Reviewer Tips
NIH biosketch 2026: the SciENcv Common Form and NIH Supplement, the 3,500-character personal statement, 5 contributions, and what reviewers read first.
NIH Deadlines 2026-2027: Standard Due Dates for R01, R21
NIH standard due dates: new R01s Feb 5, Jun 5, Oct 5; resubmissions Mar 5, Jul 5, Nov 5. R21, K99, F31 and T32 dates by activity code through 2027.